Nordeloz (Zoledronic Acid Monohydrate)

Zoledronic Acid, the active ingredient in Nordeloz, is a bisphosphonate presented as an intravenous solution for infusion use. It is employed to treat postmenopausal osteoporosis, Paget's disease of bone, bone metastases from solid tumours and hypercalcaemia of malignancy. GNH USA supplies Nordeloz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nordeloz is a bisphosphonate that reduces excessive bone turnover in several skeletal disorders. - Postmenopausal osteoporosis: improves bone mineral density and reduces fracture risk. - Paget's disease of bone: normalises abnormal bone remodeling and alleviates pain. - Bone metastases associated with solid tumours: limits skeletal‑related events and pain. - Hypercalcaemia of malignancy: rapidly lowers serum calcium levels.

Zoledronic Acid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Acute phase reaction: fever, myalgia, and flu‑like symptoms. - Nausea or vomiting. - Transient hypocalcaemia. - Headache.

Serious or Rare Side Effects: - Osteonecrosis of the jaw. - Atypical femur fracture. - Severe renal impairment or acute kidney injury. - Anaphylactic or severe hypersensitivity reactions.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Renal function: assess creatinine clearance and adjust use in impaired kidneys. - Calcium and vitamin D status: ensure adequate supplementation to prevent hypocalcaemia. - Serum calcium: monitor before and after infusion. - Concomitant nephrotoxic agents: avoid or use with caution. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Zoledronic Acid can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use of other bisphosphonates or potent nephrotoxic drugs (e.g., aminoglycosides). - High‑dose non‑steroidal anti‑inflammatory drugs that may worsen renal function. - Loop diuretics when combined with inadequate calcium intake, increasing hypocalcaemia risk.

Moderate Interactions (Monitor Closely): - Calcium or vitamin D supplements: timing should be separated from infusion to avoid binding. - Antacids containing aluminium or magnesium: may reduce absorption if oral bisphosphonate is used. - Corticosteroids: may potentiate bone loss, requiring closer monitoring. - Warfarin: monitor INR as zoledronic acid may affect coagulation parameters. - Immunosuppressants: observe for increased infection risk.